Citations

Clear

912 citation(s) found for "Yu, Caroline".

Characterizing the expression profile of 3R tau pathology in Pick’s disease
Tamvaka, Nicole , Soto‐Beasley, Alexandra I. , Gavrielatos, Marios , Ren, Yingxue , Udine, Evan, Quicksall, Zachary , Liskey, Delaney , Castanedes‐Casey, Monica , Wszołek, Zbigniew K. , Boeve, Bradley F. , Josephs, Keith A. , Blitterswijk, Marka van , Murray, Melissa E. , Roemer, Shanu F. , Ross, Owen A. , Wszolek, Z.K. , Quicksall, Zachary S , Castanedes-Casey, Monica , Boeve, Brad , Josephs, Keith A , van Blitterswijk, Marka , Murray, Melissa E , Dickson, Dennis W , Ross, Owen A , Beasley, Alexandra I , Heckman, Michael G. , Udine, Evan , Graff, Caroline , Dickson, Dennis W.

Mayo Clinic

Science Advances | May 2, 2025 | Volume: 11 | Issue: 18 | Pages: No page available

10.1126/sciadv.adt6105 | PMID 40315309 Get It

Pick’s disease (PiD) is a rare neurodegenerative disorder defined by dementia, frontotemporal lobe atrophy, and 3-repeat tau inclusions. To elucidate PiD pathobiology, we performed the first bulk transcriptomics study on PiD using short- and long-read sequencing on the parietal cortex of 28 PiD and 15 control samples. We identified several significantly differentially expressed genes, with CCL2 displaying the strongest association with 3-repeat tau pathology and increased burden in PiD compared to those in 4-repeat tau progressive supranuclear palsy (PSP) cases. Investigation of co-expressed genes and pathways suggested the involvement of mRNA processing, mitochondrial function, and immune processes in disease pathobiology. Long-read RNA sequencing on a subset of samples (eight PiD and four control) proposed novel, potentially disease-associated transcripts for AZGP1 , CD44 , HSD11B2 , and WIF1 , predicted to result in truncated proteins. In conclusion, we observed transcriptomic changes in the parietal cortex of patients with PiD that may inform into clinically relevant biomarkers and therapeutic strategies.
Stress Echo 2030 Study: A Flagship Project of the Italian Society of Echocardiography and Cardiovascular Imaging
Picano, Eugenio, Padang, Ratnasari , Kane, Garvan C. , Villarraga, Hector R. , Arruda‐Olson, Adelaide M. , Vazquez, Jesus Peteiro , Boshchenko, A , Журавлева, О. А. , Sviazova, Natalia , Balkevičienė, Laura, Djordjevic‐Dikic, Ana , Kobal, Sergio , Lisi, Matteo , Merli, Elisa , Manganelli, F, Daros, Clarissa Borguezan , D’Alfonso, Maria Grazia , Mori, Fabio , Kasprzak, Jarosław D. , Safarova, Ayten, Timofeeva, T. N. , Mosto, Hugo , Wierzbowska‐Drabik, Karina , Ratanasit, Nithima , Colonna, Paolo , Ostojić, Miodrag , Cortigiani, Lauro , Rigo, Fausto , Benfari, Giovanni , Soulis, Dimitrios , Yin, Lixue , Mazzi, Alberto, Haber, Diego M. Lowenstein, Marconi, Sofia, Tripepi, Giovanni Luigi, Nes, Michele De, Bartolacelli, Ylenia , Villari, Bruno, Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Benfari, Giovanni , Colonna, Paolo , Boshchenko, Alla , Ciampi, Quirino , Arbucci, Rosina , Zagatina, A , Kalinina, Elena , Ryabova, Tamara , Čelutkienė, Jelena , Saad, Ariel K. , Bursi, Francesca , Rodríguez‐Zanella, Hugo , Gaibazzi, Nicola , Costantino, Marco Fabio , Kovačević-Preradović, Tamara , Varga, Albert , Nikolic, Aleksandra, Cocchia, Rosangela , Pálinkás, Attila , Pálinkás, Eszter Dalma , Valente, Filipa Xavier , Wang, Yi , Heyning, Caroline M. Van De , Mazzi, Alberto, Lowenstein, Jorge , Barbieri, Andréa , Mantovani, Francesca , Pepi, Mauro , Carerj, Scipione , Pellikka, Patricia A.

Mayo Clinic

Journal of Cardiovascular Echography | May 1, 2025 | Volume: 35 | Issue: 1 | Pages: 1-7

10.4103/jcecho.jcecho_2_25 | PMID 40463758 Get It

Over the past decade, stress echocardiography has evolved from a test for assessing epicardial artery stenosis to a comprehensive functional test, targeting multiple cardiovascular parameters. The new approach includes several structured steps: (a) evaluating regional wall motion abnormalities to detect epicardial artery stenosis or vasospasm; (b) assessing pulmonary congestion and diastolic function via B-lines with lung ultrasound; (c) gauging preload and contractile reserve with volumetric echocardiography; (d) measuring coronary microvascular reserve using Doppler-based coronary flow velocity in the middistal left anterior descending artery; and (e) determining cardiac sympathetic reserve by tracking heart rate reserve on an ECG. This evolution was supported extensively by the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI), which played a key role in five areas: (1) developing the initial, curiosity-driven project; (2) disseminating protocols and results at national and international conferences, supporting logistic infrastructure and publication expenses; (3) establishing a digital platform (customized Redcap) for data entry and storage; (4) facilitating patient recruitment across 19 Italian centers; and (5) offering formal endorsement through six presidencies, adding credibility and reach beyond any single institution. The protocol quickly advanced from concept to high-impact publications, earning inclusion in 2024 specialty guidelines. Initially Italian-led, the study now includes 50 centers across 20 countries (e.g. USA and China). Beyond the 50 peer-reviewed papers published in 2016–2024, this study offers a novel, sustainable approach to cardiac stress testing, providing more information at lower costs, with zero radiation and minimal environmental impact. SIECVI’s endorsement was instrumental in amplifying the study’s rigor and outreach.
SUN-510 Metabolic effects of masculinizing hormone therapy in transgender and gender diverse individuals with prior diagnosis of polycystic ovary syndrome
Chang, Alice Y. , Davidge‐Pitts, Caroline , McNeil, John W. , McNeil, John S , McNeil, John Anderson, Herndon, Justine , Hamidi, Oksana

Mayo Clinic

Journal of the Endocrine Society | April 30, 2025 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.2434 Get It

Abstract J.A. McNeil: None. J. Herndon: None. A.Y. Chang: None. C.J. Davidge-Pitts: None. O. Hamidi: None. Background: Testosterone therapy (TT) in individuals assigned female at birth (AFAB) is linked to an atherogenic lipid profile, including lower HDL cholesterol, elevated triglycerides, and LDL cholesterol. Polycystic ovary syndrome (PCOS), characterized by androgen excess, affects 16-20% of cisgender individuals AFAB. Recent data suggests a greater PCOS prevalence in transmasculine transgender/gender diverse (TGD) individuals at 23.8% to 38.8%. Whether TT in AFAB individuals with history of PCOS triggers more adverse metabolic changes than in TGD individuals without PCOS remains uncertain. While cohort studies haven't indicated increased cardiovascular (CV) risk with TT, it's unclear if specific subgroups, such as those with PCOS, develop more CV risk factors. Objective: To compare the effects of TT on CV risk factors in TGD individuals with a history of PCOS vs. TGD without PCOS. Methods: We retrospectively reviewed 454 records in a multispecialty TGD clinic to identify 62 with PCOS, and 132 controls without PCOS (1:2 case-control ratio) matched on age. Data included longitudinal vital signs, metabolic profiles, and details on psychiatric and medical conditions. PCOS diagnosis was validated using Rotterdam criteria. Exclusions comprised individuals under 14, those on puberty-suppressing gonadotropin-releasing hormone analogues, or already undergoing TT at the initial visit. Results: Among 454 subjects, 62 (13.7%) were diagnosed with PCOS. At baseline, PCOS was associated with significantly higher BMI (p < 0.01), SBP (p = 0.01), prevalence of obesity (p < 0.01), obstructive sleep apnea (OSA, p < 0.01), and type 2 diabetes mellitus (p = 0.01). History of PCOS was associated with greater metformin use (p < 0.001), CV disease history (p = 0.003), and transaminitis (p = 0.03). After weight adjustment, only baseline metformin use differed significantly between PCOS and controls. 140 (72.2%) received TT, 50 (80.6%) with PCOS and 90 (68.2%) controls. After weight adjustment, notable baseline changes in ALT (p = 0.006), HDL (p < 0.001), LDL (p < 0.001), hypertension, and hypertriglyceridemia prevalence (p=0.001) were observed in the full cohort on TT. Compared to controls, PCOS patients on TT exhibited higher hypercholesterolemia prevalence (p = 0.03) and elevated bioavailable testosterone (p = 0.04) after weight correction. Conclusions: TGD Individuals with PCOS had significantly worse CV risk profile compared to controls before starting TT attributed to greater weight. Significant changes in ALT, LDL, HDL, and prevalence of hypertriglyceridemia were seen across the entire TGD cohort treated with TT, but only hypercholesterolemia prevalence remained significantly higher in TGD PCOS cases on TT when corrected for weight. PCOS history was not associated with greater changes in CV risk factors in TGD individuals starting TT. Sunday, June 2, 2024
Risk Factors for Thyroid Function Test Abnormalities During Pregnancy: A Systematic Review of the Literature to Validate Current Risk Factors and Identify Novel Ones
Liu, Yindi , Osinga, J. , Bliddal, Sofie , Alexander, Erik K. , Dosiou, Chrysoula , Boelaert, Kristien , Brenta, Gabriela , Krabbendam, Elise, Eaton, Jennifer L., Guan, Haixia , Nguyen, Caroline T. , Pearce, Elizabeth N. , Leung, Angela M. , Korevaar, Tim I.M. , Osinga, Joris A J , Bliddal, Sofie , Brenta, Gabriela , Guan, Haixia , Lee, Sun Y , Pearce, Elizabeth N , Leung, Angela M , Dosiou, Chrysoula , Maraka, Spyridoula , Morris, Lilah F. , Shan, Zhongyan , Dhillon‐Smith, Rima , Peeters, Robin P.

Mayo Clinic

Thyroid® | April 29, 2025 | Volume: 35 | Issue: 5 | Pages: 553-575

10.1089/thy.2024.0743 | PMID 40296843 Get It

Clinical characteristics and outcomes of primary orbital lymphoma
Wang, Kenny Y. , Kim, B. Michelle, Yu, Caroline , Welk, Grant M. , Churchill, Robert , White, Launia J. , Hodge, David O. , Dalvin, Lauren A. , Tooley, Andrea A. , Yu, Caroline Y, Churchill, Robert A , Dalvin, Lauren A

Mayo Clinic

European Journal of Ophthalmology | April 29, 2025 | Volume: 35 | Issue: 5 | Pages: 1776-1785

10.1177/11206721251338705 | PMID 40296647 Get It

Purpose To describe the clinical characteristics, histopathologic subtype distribution, treatment, and outcomes of patients with primary orbital lymphoma. Major Findings There were 126 biopsy-confirmed cases of primary orbital lymphoma, with 81 (64.3%) female and 110 (87.3%) white. The average age at diagnosis was 62.7 ± 13.9 years. There were 26 (20.6%) cases with bilateral involvement. The most frequent lymphoma subtype was MALT lymphoma (N = 76, 60.3%), followed by diffuse large B-cell lymphoma (N = 18, 14.3%) and follicular lymphoma (N = 12, 9.5%). Prognosis was generally favorable, as local recurrence occurred in only 14 (11.1%) patients and final best corrected visual acuity (BCVA) loss of >1 line was seen in 30 (28.0%) patients. Bilateral lymphoma and advanced stage (Ann Arbor Stage III or IV) at presentation were associated with increased risk of local recurrence ( p = 0.0025, p = 0.049). Improved disease-specific survival was associated with diagnosis at Stage I or II ( p = 0.013), MALT subtype ( p = 0.034), or lack of chemotherapy requirement as primary treatment ( p = 0.0073). Conclusions In this single center academic cohort, MALT lymphoma subtype was most common. Overall orbital recurrence frequency was low, and bilateral lymphoma and advanced stage were associated with increased risk of local recurrence. MALT lymphoma subtype was associated with improved disease-specific survival. Long-term follow-up showed that most patients retained good visual acuity in the affected eye(s).
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia
Liu, Xulin , Cortez, Kasey, Poos, Jackie M. , Illán‐Gala, Ignacio , Heuer, Hilary W. , Forsberg, Leah K. , Casaletto, Kaitlin B. , Memel, Molly , Barmada, Sami J. , Clark, David , Darby, Ryan, Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Kantarci, Kejal, Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Roberson, Erik D. , Rogalskı, Emily , Bouzigues, Arabella , Russell, Lucy L. , Foster, Phoebe H. , Ferry‐Bolder, Eve , Masellis, Mario, Jiskoot, Lize C. , Laforce, Robert, Graff, Caroline , Galimberti, Daniela, Vandenberghe, Rik, Santana, Isabel, Xiong, Chengjie , Sorbi, Sandro , Otto, Markus , Pasquier, Florence, Ducharme, Simon , Butler, Christopher , Ber, Isabelle Le, Synofzik, Matthis , Moreno, Fermín , Boxer, Adam L. , Rosen, Howie, Rohrer, Jonathan D., Kantarci, Kejal , Galimberti, Daniela , Bocchetta, Martina , Moreno, Fermín , Boeve, Brad F, Roberson, Erik , Kantarci, Kejal , Pascual, Belen , Synofzik, Matthis , Xiong, Chengjie , Domoto-Reilly, Kimiko , Barmada, Sami , Otto, Markus , Illán-Gala, Ignacio , Galimberti, Daniela , Russell, Lucy L , Bocchetta, Martina , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Boer, Sterre C.M. de , Appleby, Brian S. , Bozoki, Andrea C , Cobigo, Yann , Dickerson, Bradford Clark , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Irwin, David J. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Bayram, Ece , Swieten, John C. van , Seelaar, Harro , Sánchez‐Valle, Raquel , Laforce, Robert , Vandenberghe, Rik , Mendonça, Alexandre de , Tiraboschi, Pietro , Santana, Isabel , Gerhard, Alexander , Pasquier, Florence , Ber, Isabelle Le , Finger, Elizabeth C. , Rowe, James B. , Borroni, Barbara , Boeve, Bradley F. , Pijnenburg, Yolande A.L. , Rohrer, Jonathan D. , Tartaglia, Maria Carmela

Mayo Clinic

Alzheimer's & Dementia | April 25, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.14608 | PMID 40277074 Get It

AbstractINTRODUCTIONHigher male prevalence in sporadic behavioral variant frontotemporal dementia (bvFTD) has been reported. We hypothesized differences in phenotypes between genetic and sporadic bvFTD females resulting in underdiagnosis of sporadic bvFTD females.METHODSWe included genetic and sporadic bvFTD patients from two multicenter cohorts. We compared behavioral and cognitive symptoms, and gray matter volumes, between genetic and sporadic cases in each sex.RESULTSFemales with sporadic bvFTD showed worse compulsive behavior (p = 0.026) and language impairments (p = 0.024) compared to females with genetic bvFTD (n = 152). Genetic bvFTD females had smaller gray matter volumes than sporadic bvFTD females, particularly in the parietal lobe.DISCUSSIONFemales with sporadic bvFTD exhibit a distinct clinical phenotype compared to females with genetic bvFTD. This difference may explain the discrepancy in prevalence between genetic and sporadic cases, as some females without genetic mutations may be misdiagnosed due to atypical bvFTD symptom presentation.Highlights Sex ratio is equal in genetic behavioral variant of frontotemporal dementia (bvFTD), whereas more males are present in sporadic bvFTD. Distinct neuropsychiatric phenotypes exist between sporadic and genetic bvFTD in females. Phenotype might explain the sex ratio difference between sporadic and genetic cases.
Abstract 2531: Novel staining method for visualization, isolation and processing of intracranial brain tumors
Herfindahl-Quint, Anders, Jain, Sonia , Doherty, Caroline Lloyd , Zhang, Wenjuan , Burgenske, Danielle M. , Sarkaria, Jann N.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2531-2531

10.1158/1538-7445.am2025-2531 Get It

Abstract Background and Objective: Glioblastoma (GBM) is most common primary brain tumor with dire need of novel therapeutics. Studies with intracranial tumors are required for robust characterization and development of novel drugs for brain cancer. Tumor harvest and processing is an important aspect to study pharmacokinetics, pharmacodynamics, drug delivery, and tumor evolution. Typically, delineating and dissecting tumor from surrounding brain for varied downstream processes is dependent on the distinct morphology of the tumor and/or expression of fluorescent marker. However, genetic modification of the tumor cells for the expression of fluorescent protein is not always possible, especially for patient-derived xenograft (PDX) tumor models. Thus, we have developed a dye-based staining method to confidently visualize tumor in the brain and assessed usability of isolated tumors for drug and DNA analysis. Methodology: Whole brains were harvested from mice with intracranial Mayo GBM PDX tumors and stored at -80oC freezer. Few days prior to staining, brains were transferred to -20oC freezer. Brain was cut into 1 mm thick coronal sections and transferred onto glass slides. Slices were covered with toluidine blue (TB) solution (0.05 to 10 mg/mL) for 45 s. Excess stain solution was removed, and slices were observed under white light. Regions of tumor became more transparent, while normal brain remained opaque. This enabled dissection of tumor from normal brain for downstream analyses. Results: TB concentration (0.05 to 10 mg/mL) was optimized to stain 1 mm thick sections of fresh frozen brain, and the best contrast between tumor to normal brain was observed at 0.1-0.3 mg/mL. TB aided differential visualization of tumors in several PDX models - GBM12, GBM43, GBM39 and GBM108 - suggesting broad applicability. To evaluate the accuracy of TB staining, brain with PDX tumor transduced with pSINeGFP/fLuc2 was observed by both TB staining and eGFP fluorescence. This analysis demonstrated excellent concordance across 6 animals with three distinct PDX models. Genomic DNA was isolated from tumor dissected under TB guidance and analyzed by PCR for primers specific for murine vs human PTGER2. 50-70% of the DNA in tumor samples was detected to be of human origin while normal brain tissue had 90-95% of the mouse DNA highlighting the specificity of TB stain for tumor detection. Tumors from drug treated GBM108 PDX were isolated under TB guidance and comparable drug levels were detected by LC-MS/MS as analyzed in GFP-assisted tumor samples. Conclusion: Staining fresh frozen thick brain sections with toluidine blue enables visualization of tumor from normal brain regions that is compatible with varied downstream processes. Development of such staining assays can help faster and easier tumor processing and is not dependent on genetic modification of tumor cells prior to experimentation. Citation Format: Sonia Jain, Anders Herfindahl-Quint, Caroline D. Doherty, Wenjuan Zhang, Danielle M. Burgenske, Jann N. Sarkaria. Novel staining method for visualization, isolation and processing of intracranial brain tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2531.
Brain Volume Loss Correlation with Clinical Severity and Progression in Individuals with CSF1R-ALSP: Findings from the ILLUMINATE Prospective Natural History Study (P4-3.017)
Koehler, Wolfgang, Bergner, Caroline, Hayer, Stefanie N. , Murphy, Jennifer Orthmann, Meier, Andreas , Doros, Gheorghe , Rajagovindan, Rajasimhan, Kaufmann, Petra, Lynch, David R. , Gelfand, Jeffrey M. , Wolf, Nicole I , Schöls, Ludger , Finger, Elizabeth C. , Meier, Andreas, Wade, Charles , McLaren, Donald G. , Rajagovindan, Raj, Wszołek, Zbigniew K.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208880 Get It

Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Singh, Siddharth , Nguyen, J. , Fudman, David , Gerich, Mark E. , Hudesman, David , McConnell, Ryan , Flynn, Ann D. , Hwang, Caroline, Sprung, Brandon, Gaidos, Jill , Mattar, Mark , Metwally, Mark, Ali, Tauseef , Narula, Neeraj, Rosenfeld, Greg , Cross, Raymond, Gaytán, Josep María, Gurrola, Emily-Sophinie, Patel, Sagar , Melmed, Gil , Weaver, Sarah , Power, Sydney, Jairath, Vipul , Hou, Jason K. , Jairath, Vipul , Jairath, Vipul , Fudman, David I , Hudesman, David , Flynn, Ann D , Sprung, Brandon , Gaidos, Jill K J , Ali, Tauseef , Hoentjen, Frank , Bessissow, Talat , Patel, Sagar , Siegel, Corey A , Zou, Guangyong , Jairath, Vipul , Jairath, V , Jairath, V , Melmed, Gil Y , Nguyen, Jasmine D, Shah, Shiraz Ali , Lukin, Dana J. , Rubin, David T. , Hashash, Jana G. , Ma, C , Narula, Neeraj , Bessissow, Talat , McCurdy, Jeffrey D , Ananthakrishnan, Ashwin N. , Gurrola, Emily-Sophinie, Power, Sydney , Zou, Guangyong

Mayo Clinic

BMJ Open Gastroenterology | April 1, 2025 | Volume: 12 | Issue: 1 | Pages: e001615

10.1136/bmjgast-2024-001615 | PMID 40164445 Get It

Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologically active bowel inflammation, and it is uncertain whether changing alternative advanced therapies in asymptomatic patients with IBD will reduce bowel inflammation and achieve durable deep remission. Methods and analysis The QUality Outcomes Treating IBD to Target (QUOTIENT) study is an open-label, multicentre, pragmatic, randomised, controlled trial that aims to compare the efficacy and safety of switching to an alternative advanced therapy targeting endoscopic/radiological remission (treat-to-target) versus continuing the initial, or index, advanced therapy, in asymptomatic patients with IBD with moderate-to-severe endoscopic/radiological bowel inflammation. Enrolment is planned for ~250 participants in Canada/USA, randomised 1:1 to switching to alternative advanced therapy or continuing index advanced therapy, and then followed 104 weeks within routine clinical practice. Patient-reported outcomes measure efficacy and quality of life/treatment burden/safety. Primary endpoint is the time from randomisation to treatment failure. Ethics and dissemination The study is conducted in compliance with the protocol, ICH Good Clinical Practice, applicable regulatory requirements and appropriate review boards/independent ethics committees (approval numbers: Pro00077486; Pro00061437; STUDY00002062; 22-004171; i22-01269; IRB22-0890; IRB_00154397; 2000032384; SHIRB#2022.095-2; STUDY00007146; MMC#2024-18; REB#125290; 17784; Pro00142214; 20240660-01H), with documented written informed consent. Findings will be disseminated through peer-reviewed journals, scientific presentations, and publicly available Patient-Centered Outcomes Research Institute (PCORI) websites, including lay summaries. The Crohn’s & Colitis Foundation Education, Support, and Advocacy Department, and our patient advocacy stakeholder, will develop educational and marketing resources to communicate findings to a broad audience (>250 000 patients/caregivers/healthcare professionals). Trial registration number NCT05230173 .
Activin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease
Bian, Xiaohui , Snow, Zachary K. , Zinn, C. , Gowan, Cody, Conley, Sabena M., Bratulin, Anastasia L. , Elhusseiny, Khaled , Miller, Jordan D. , Kirkland, James L. , Lerman, Lilach O. , Zinn, Caroline J, Gowan, Cody C , Elhusseiny, Khaled M , Miller, Jordan , Kirkland, James L , Lerman, Lilach O , Smith, Anastasia , Bian, Xiaohui , Tchkonia, Tamar , Hickson, LaTonya J.

Mayo Clinic

Kidney360 | March 30, 2025 | Volume: 6 | Issue: 8 | Pages: 1278-1291

10.34067/kid.0000000776 | PMID 40152935 Get It

Key Points Activin A is implicated in profibrotic and prosenescent kidney injury and correlates with kidney injury markers in animals and humans. Follistatin, through activin A antagonism, reduces senescence burden, macrophage infiltration, and proinflammatory pathway activation in murine diabetic kidney disease. Follistatin and other antagonists of activin A signaling pathways may be promising, novel therapeutics for diabetic kidney disease. Background Circulating activin A, an inflammatory mediator implicated in profibrotic kidney injury and cellular senescence-induced adipose tissue dysfunction, is increased in human diabetic kidney disease (DKD) and directly correlates with kidney dysfunction. We tested the hypothesis that activin A increases kidney injury, senescent cell abundance, and macrophage infiltration in DKD and antagonism through follistatin (FS) therapy diminishes these effects. Methods An accelerated nephropathy type 2 diabetes (db/db) mouse model was generated by implantation of angiotensin II-loaded osmotic minipumps resulting in increased albuminuria and glomerular and tubular injury. Kidney repair effects of FS (5 µ g intraperitoneal; two doses) were assessed through markers of kidney injury, fibrosis, inflammation, cellular senescence, and macrophage infiltration. In vitro studies examined antiactivin effects of FS on high glucose-exposed human monocytes, renal fibroblasts, and renal tubule epithelial cells. Results Activin A antagonism with FS reduced senescence (p19), proinflammatory (including senescence-associated secretory phenotype), and profibrotic markers including activin A. FS improved kidney morphology, restored podocyte markers (nephrin and Wilms tumor-1), and reduced kidney injury biomarkers, albuminuria and kidney fibrosis. FS decreased kidney macrophage and leukocyte infiltration and absent in melanoma 2 inflammasome activation. FS seemed to suppress inflammation through the toll-like receptor-4/NF kappa-light-chain-enhancer of activated B cells pathway in vivo further supported in human macrophages in vitro . In addition, FS reduced hyperglycemia-induced renal fibroblast activation and renal tubule epithelial cell senescence in vitro . Conclusions Activin A is a mediator of kidney injury through macrophage-associated inflammation in murine DKD. FS acts through senomorphic activities which inhibit profibrotic, proinflammatory, and prosenescence signaling by activin A. Hence, antiactivin targeting may aid in the development of a promising, novel therapeutic for DKD.